Clinical trials: Individual Psychiatric Disorder
Alzheimer's Disease
3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease
This study will evaluate the effect of 150 mg MSDC-0160 taken daily for 90 days compared to the effect of placebo on changes in brain glucose utilization using FDG-PET and cognition in older persons with mild Alzheimer's disease.
- Trial name
- NCT01374438
- Testing
- MSDC-0160
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Metabolic Solutions Development Company
Alzheimer Disease
Autologous Human Adipose-Derived Mesenchymal Stem Cells in Alzheimer's Disease
This is a single patient emergency expanded access clinical study to assess the safety of administering autologous AdMSCs to an incurable Alzheimer disease patient.
- Trial name
- NCT04855955
- Testing
- Adipose-Derived Mesenchymal Stem Cells
- Sponsor
- Celltex Therapeutics Corporation
Schizophrenia
A Study to Evaluate the Overall Effects of Treatment With Abbreviated CT-156 in People With Schizophrenia
An exploratory, double-arm, 4-week study to explore the feasibility and acceptability of abbreviated treatment with CT-156 for people with Schizophrenia.
- Trial name
- NCT06136936
- Testing
- CT-156-C-001
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Click Therapeutics, Inc.
Schizophrenia
CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia
This study is open to adults with schizophrenia. Schizophrenia can affect the way a person thinks, their memory and their mental functioning.
- Trial name
- NCT04860830
- Testing
- Iclepertin
- Where
- 110 sites in United States, Argentina and 16 more
- Volunteers
- 609 people
- Sponsor
- Boehringer Ingelheim
Alzheimer Disease
A Phase I Study of DDN-A-0101 in Healthy Volunteers and Elder People
The study is a Phase I, randomized double-blind, placebo-controlled, single and multiple dosing, dose-escalation study of the oral administration of DDN-A-0101 in healthy adults and elderly subjects
- Trial name
- NCT06367426
- Testing
- DDN-A-0101 (SAD), DDN-A-0101 (MAD)
- Where
- South Korea
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Pharmacobio
Cadmium Exceeds the Standard
Study on Neuropsychiatric Behavior in Cadmium-exposed People
This study hypothesized that excessive cadmium is related to clinical pain, depression, and cognitive impairment, and that related indicators will improve after cadmium is eliminated.
- Trial name
- NCT06572566
- Testing
- Non-invasive examination and assessment.
- Where
- China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Jianersheng (Zhuhai) Pharmaceutical Technology Co., Ltd.
Eating Disorders
The Use of Smart Devices in Capturing Digital Biomarkers in Eating Disorders
This study aims to explore how smart devices can be used to monitor the health of individuals with eating disorders. Eating disorders are serious mental health conditions that impact both mental and physical health.
- Trial name
- NCT06544226
- Testing
- UH100
- Where
- United Kingdom
- Volunteers
- 130 people
- Sponsor
- Univa Health
Abuse Prevention
Protect Yourself: Abuse Prevention for People With Intellectual Disabilities
The purpose of this study is to help individuals and their caregivers develop a plan on how to recognize, deal with and respond to abusive situations.
- Trial name
- AP4ID (NCT03998605)
- Testing
- Abuse Prevention Program, Control Condition
- Where
- United States
- Sponsor
- Double S Instructonal Systems
Engagement, Patient, Mood
SimpleC Wellness Platform With Social Robot Interaction
This implementation study will be conducted to test a Socially-Assistive Robot (SAR) system for residents in an Assisted Living environment. The goal of the SAR system is to enhance social engagement and connectedness.
- Conditions
- Engagement, Patient, Mood, Quality of Life, Aging
- Trial name
- NCT05296239
- Testing
- SimpleC Wellness Platform with Social Robot Interaction
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- SimpleC, LLC
Narcolepsy
This is a Study to Determine the Effect of Multiple Doses of an Investigational Drug, Taken by Mouth, in People With Narcolepsy-cataplexy. Accepting Both Males and Females Ages of 18 Years to 55 Years. This Study Will be Conducted in the US and Will Require Approximately 13 Weeks Participation.
This is a study to determine the effect of multiple doses of an investigational drug, taken by mouth, in people with Narcolepsy-cataplexy.
- Trial name
- NCT05015673
- Testing
- SEP363856
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder, Bipolar I and Bipolar II
Bipolar Proteomic Assay Validation Study
The purpose of this study is to validate a set of signatures, based on a panel of proteomic markers, that discriminate BDI, BDII, and MDD in people seeking treatment for a depressive episode.
- Trial name
- NCT02746367
- Testing
- Diagnostic test (LDT)
- Where
- 5 sites in United States
- Volunteers
- 261 people
- Sponsor
- Myriad Genetic Laboratories, Inc.
Early Alzheimer's Disease
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD).
- Trial name
- NCT07033494
- Testing
- MK-2214
- Where
- 80 sites in United States, Argentina and 9 more
- Volunteers
- 340 people
- Sponsor
- Merck Sharp & Dohme LLC
Depression, Anxiety
Meru Health Program for Cancer Patients With Depression and Anxiety
The primary objective of this study is to evaluate clinical outcomes among people with cancer who participate in a 12-week therapist-supported digital mental health intervention (DMHI) called the Meru Health Program (MHP).
- Trial name
- NCT05588622
- Testing
- Meru Health Program
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Meru Health, Inc.
Memory Impairment, Age-related Cognitive Decline
Development of an Innovative Health Ingredient From Marine By-products for the Healthy Aging
This interventional, randomised, placebo-controlled and double-blind study aims to evaluate the effect of a dietary supplementation with a blue fish hydrolysate derived from marine by-products, containing peptides and n-3…
- Trial name
- BRAINBOOSTER (NCT04910399)
- Testing
- Blue fish hydrolysate
- Where
- 2 sites in France
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Abyss Ingredients
Migraine Disorders, Headache Disorders, Primary
Individualized Prediction of Migraine Attacks Using a Mobile Phone App and Fitbit
This trial is collaboration between Mayo Clinic, Second Opinion Health (Simon Bloch, simon@somobilehealth.com 408-981-3814) and Allergan.
- Conditions
- Migraine Disorders, Headache Disorders, Primary, Headache Disorders, Brain Diseases
- Trial name
- Migraine Alert (NCT02910921)
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Second Opinion Health
Borderline Personality Disorder
A Study to Test Different Doses of BI 1358894 and Find Out Whether They Reduce Symptoms in People With Borderline Personality Disorder
This study is open to adults with borderline personality disorder. The purpose of this study is to find out whether a medicine called BI 1358894 helps to reduce symptoms in people with borderline personality disorder.
- Trial name
- NCT04566601
- Testing
- BI 1358894
- Where
- 67 sites in United States, Argentina and 13 more
- Volunteers
- 390 people
- Sponsor
- Boehringer Ingelheim
Borderline Personality Disorder, Attention Deficit Hyperactivity Disorder
A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder
This study is open to adults with certain mental health conditions. The purpose of this study is to find out how a medicine called BI 3031185 is tolerated by people with certain mental health conditions.
- Trial name
- NCT07001475
- Testing
- BI 3031185
- Where
- 7 sites in Germany
- Volunteers
- 78 people
- Sponsor
- Boehringer Ingelheim
Generalized Anxiety Disorder (GAD), Major Depressive Disorder (MDD)
AI-Supported Therapy for Depression and Anxiety Compared With Standard CBT
This study is a pivotal, randomised, controlled, non-inferiority trial evaluating "Nook," an AI-delivered, neurosymbolic, clinician-supervised digital psychological intervention for depression and anxiety, compared with standard…
- Trial name
- NCT07620340
- Testing
- AI-Digital CBT, Cognitive Behavioural Therapy
- Volunteers
- 400 people
- Sponsor
- PsyScale
Aging, Mortality
Human Observatory Study
The Human Observatory Study is a prospective observational and ecological surveillance study building a continuously-updating world model for human health, disease, and death at the individual and population level.
- Conditions
- Aging, Mortality, All-cause Mortality, Life Expectancy
- Trial name
- HOS (NCT07646782)
- Testing
- Multi-Domain Ecological and Clinical Data Linkage
- Where
- United States
- Volunteers
- 1,000,000 people, healthy volunteers welcome
- Sponsor
- Longevity Metrics, Inc.
Osteoarthritis, Knee
A Telehealth Study of a Wearable Electroceutical & Sports Sleeve for Knee Osteoarthritis Pain Relief & Improved Function
The purpose of this telemedicine 24-person open-label study is to evaluate the safety and usability of a proprietary wearable microcurrent electroceutical (a device that delivers micro-ampere electronic pulses) made by Healables…
- Trial name
- HEAL01WMCOA1 (NCT04938271)
- Testing
- HEAL-122 microcurrent electroceutical with e-textile sports knee sleeve
- Where
- Israel
- Volunteers
- 24 people
- Sponsor
- Healables Ltd.